These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 19505953)
1. Identification and characterization of a selective radioligand for ELOVL6. Shimamura K; Takahashi H; Kitazawa H; Miyamoto Y; Nagumo A; Tang C; Dean D; Nagase T; Sato N; Tokita S J Biochem; 2009 Sep; 146(3):429-37. PubMed ID: 19505953 [TBL] [Abstract][Full Text] [Related]
2. 5,5-Dimethyl-3-(5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-1-phenyl-3-(trifluoromethyl)-3,5,6,7-tetrahydro-1H-indole-2,4-dione, a potent inhibitor for mammalian elongase of long-chain fatty acids family 6: examination of its potential utility as a pharmacological tool. Shimamura K; Kitazawa H; Miyamoto Y; Kanesaka M; Nagumo A; Yoshimoto R; Aragane K; Morita N; Ohe T; Takahashi T; Nagase T; Sato N; Tokita S J Pharmacol Exp Ther; 2009 Jul; 330(1):249-56. PubMed ID: 19359527 [TBL] [Abstract][Full Text] [Related]
3. Discovery and characterization of a novel potent, selective and orally active inhibitor for mammalian ELOVL6. Shimamura K; Nagumo A; Miyamoto Y; Kitazawa H; Kanesaka M; Yoshimoto R; Aragane K; Morita N; Ohe T; Takahashi T; Nagase T; Sato N; Tokita S Eur J Pharmacol; 2010 Mar; 630(1-3):34-41. PubMed ID: 20045404 [TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of a novel 3-sulfonyl-8-azabicyclo[3.2.1]octane class of long chain fatty acid elongase 6 (ELOVL6) inhibitors. Nagase T; Takahashi T; Sasaki T; Nagumo A; Shimamura K; Miyamoto Y; Kitazawa H; Kanesaka M; Yoshimoto R; Aragane K; Tokita S; Sato N J Med Chem; 2009 Jul; 52(14):4111-4. PubMed ID: 19522500 [TBL] [Abstract][Full Text] [Related]
5. Synthesis and evaluation of a novel indoledione class of long chain fatty acid elongase 6 (ELOVL6) inhibitors. Takahashi T; Nagase T; Sasaki T; Nagumo A; Shimamura K; Miyamoto Y; Kitazawa H; Kanesaka M; Yoshimoto R; Aragane K; Tokita S; Sato N J Med Chem; 2009 May; 52(10):3142-5. PubMed ID: 19388647 [TBL] [Abstract][Full Text] [Related]
6. Discovery of novel benzoxazinones as potent and orally active long chain fatty acid elongase 6 inhibitors. Mizutani T; Ishikawa S; Nagase T; Takahashi H; Fujimura T; Sasaki T; Nagumo A; Shimamura K; Miyamoto Y; Kitazawa H; Kanesaka M; Yoshimoto R; Aragane K; Tokita S; Sato N J Med Chem; 2009 Nov; 52(22):7289-300. PubMed ID: 19883081 [TBL] [Abstract][Full Text] [Related]
7. High-throughput assay for long chain fatty acyl-CoA elongase using homogeneous scintillation proximity format. Shimamura K; Miyamoto Y; Kitazawa H; Kobayashi T; Kotani H; Tokita S Assay Drug Dev Technol; 2009 Apr; 7(2):124-32. PubMed ID: 19505229 [TBL] [Abstract][Full Text] [Related]
8. Development of a high-throughput screening assay for stearoyl-CoA desaturase using rat liver microsomes, deuterium labeled stearoyl-CoA and mass spectrometry. Soulard P; McLaughlin M; Stevens J; Connolly B; Coli R; Wang L; Moore J; Kuo MS; LaMarr WA; Ozbal CC; Bhat BG Anal Chim Acta; 2008 Oct; 627(1):105-11. PubMed ID: 18790133 [TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of a novel 2-azabicyclo[2.2.2]octane class of long chain fatty acid elongase 6 (ELOVL6) inhibitors. Sasaki T; Nagase T; Takahashi T; Nagumo A; Shimamura K; Miyamoto Y; Kitazawa H; Kanesaka M; Yoshimoto R; Aragane K; Tokita S; Sato N Bioorg Med Chem; 2009 Aug; 17(15):5639-47. PubMed ID: 19596583 [TBL] [Abstract][Full Text] [Related]
10. Elovl6 promotes nonalcoholic steatohepatitis. Matsuzaka T; Atsumi A; Matsumori R; Nie T; Shinozaki H; Suzuki-Kemuriyama N; Kuba M; Nakagawa Y; Ishii K; Shimada M; Kobayashi K; Yatoh S; Takahashi A; Takekoshi K; Sone H; Yahagi N; Suzuki H; Murata S; Nakamuta M; Yamada N; Shimano H Hepatology; 2012 Dec; 56(6):2199-208. PubMed ID: 22753171 [TBL] [Abstract][Full Text] [Related]
11. Lead discovery for mammalian elongation of long chain fatty acids family 6 using a combination of high-throughput fluorescent-based assay and RapidFire mass spectrometry assay. Takamiya M; Sakurai M; Teranishi F; Ikeda T; Kamiyama T; Asai A Biochem Biophys Res Commun; 2016 Nov; 480(4):721-726. PubMed ID: 27793673 [TBL] [Abstract][Full Text] [Related]
12. Deletion of ELOVL6 blocks the synthesis of oleic acid but does not prevent the development of fatty liver or insulin resistance. Moon YA; Ochoa CR; Mitsche MA; Hammer RE; Horton JD J Lipid Res; 2014 Dec; 55(12):2597-605. PubMed ID: 25281760 [TBL] [Abstract][Full Text] [Related]
13. Two modes of regulation of the fatty acid elongase ELOVL6 by the 3-ketoacyl-CoA reductase KAR in the fatty acid elongation cycle. Naganuma T; Kihara A PLoS One; 2014; 9(7):e101823. PubMed ID: 25003994 [TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of selective keto-1,2,4-oxadiazole-based tryptase inhibitors. Palmer JT; Rydzewski RM; Mendonca RV; Sperandio D; Spencer JR; Hirschbein BL; Lohman J; Beltman J; Nguyen M; Liu L Bioorg Med Chem Lett; 2006 Jul; 16(13):3434-9. PubMed ID: 16644215 [TBL] [Abstract][Full Text] [Related]
15. Novel qualitative aspects of tissue fatty acids related to metabolic regulation: lessons from Elovl6 knockout. Shimano H Prog Lipid Res; 2012 Jul; 51(3):267-71. PubMed ID: 22266797 [TBL] [Abstract][Full Text] [Related]
16. Expression and characterization of recombinant fungal acetyl-CoA carboxylase and isolation of a soraphen-binding domain. Weatherly SC; Volrath SL; Elich TD Biochem J; 2004 May; 380(Pt 1):105-10. PubMed ID: 14766011 [TBL] [Abstract][Full Text] [Related]